Literature DB >> 9888471

Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines.

R Kröning1, D Katz, A K Lichtenstein, G T Nagami.   

Abstract

Pathological studies suggest that cisplatin injures different portions of the nephron to different extents. To investigate this issue further, we examined the cytotoxicity and uptake of cisplatin in cell lines derived from S1 and S3 proximal tubule and distal convoluted tubule segments isolated from a mouse carrying the SV40 large T-antigen transgene. S1 cells displayed the highest sensitivity to cisplatin cytotoxicity, followed by S3 and distal convoluted tubule (DCT) cells. These differences in cytotoxicity did not correlate with differences in cisplatin uptake. Cytotoxic concentrations of cisplatin triggered apoptosis in all three cell lines. Although BAX and BCL-2 expression was similar among the three cell lines, the expression of the anti-apoptotic protein, BCL-X(L), was significantly lower in S1 cells than in S3 and DCT cells, and this may have contributed to the heightened sensitivity of S1 cells. Cisplatin transport characteristics demonstrated a saturable component of cisplatin uptake and differences in apparent K(M) and Vmax values among the three cell lines. The three cell lines were 43- to 176-fold more sensitive to cisplatin than to carboplatin. This distinction between the two drugs could not be fully explained by differences in the uptake rates of carboplatin and cisplatin. We conclude that cells from different portions of the nephron display different sensitivities to cisplatin, different transport characteristics for cisplatin and different levels of expression of BCL-X(L). In addition, the relative resistance of renal cells to carboplatin vs cisplatin is mostly due to the differential effects that follow internalization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9888471      PMCID: PMC2362192          DOI: 10.1038/sj.bjc.6690047

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Intracellular metabolites of cisplatin in the rat kidney.

Authors:  P Mistry; C Lee; D C McBrien
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine.

Authors:  S P Binks; M Dobrota
Journal:  Biochem Pharmacol       Date:  1990-09-15       Impact factor: 5.858

3.  [Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients].

Authors:  J H Guo
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1992-03

4.  Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules.

Authors:  H R Brady; B C Kone; M E Stromski; M L Zeidel; G Giebisch; S R Gullans
Journal:  Am J Physiol       Date:  1990-05

5.  Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.

Authors:  G A Hospers; N H Mulder; B de Jong; L de Ley; D R Uges; A M Fichtinger-Schepman; R J Scheper; E G de Vries
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

6.  Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin.

Authors:  R Parti; W Wolf
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.

Authors:  S C Mann; P A Andrews; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs.

Authors:  T Miyashita; J C Reed
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

9.  SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumours in transgenic mice.

Authors:  R D Palmiter; H Y Chen; A Messing; R L Brinster
Journal:  Nature       Date:  1985 Aug 1-7       Impact factor: 49.962

Review 10.  Drug-target interactions: only the first step in the commitment to a programmed cell death?

Authors:  C Dive; J A Hickman
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

View more
  3 in total

1.  Exogenous Gene Transmission of Isocitrate Dehydrogenase 2 Mimics Ischemic Preconditioning Protection.

Authors:  Alexander L Kolb; Peter R Corridon; Shijun Zhang; Weimin Xu; Frank A Witzmann; Jason A Collett; George J Rhodes; Seth Winfree; Devin Bready; Zechariah J Pfeffenberger; Jeremy M Pomerantz; Takashi Hato; Glenn T Nagami; Bruce A Molitoris; David P Basile; Simon J Atkinson; Robert L Bacallao
Journal:  J Am Soc Nephrol       Date:  2018-01-25       Impact factor: 10.121

2.  Cisplatin nephrotoxicity: molecular mechanisms.

Authors:  Marie H Hanigan; Prasad Devarajan
Journal:  Cancer Ther       Date:  2003

3.  In Vivo siRNA Delivery and Rebound of Renal LRP2 in Mice.

Authors:  Michael T Eadon; Ying-Hua Cheng; Takashi Hato; Eric A Benson; Joseph Ipe; Kimberly S Collins; Thomas De Luca; Tarek M El-Achkar; Robert L Bacallao; Todd C Skaar; Pierre C Dagher
Journal:  J Drug Deliv       Date:  2017-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.